# Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

> **NCT06343402** · PHASE1 · RECRUITING · sponsor: **TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)** · enrollment: 350 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer
- Metastatic Non-Small Cell Lung Cancer
- NSCLC
- KRAS G12C
- Metastatic Lung Cancer
- Advanced Lung Carcinoma

## Interventions

- **DRUG:** BBO-8520
- **DRUG:** Pembrolizumab
- **DRUG:** BBO-10203

## Key facts

- **NCT ID:** NCT06343402
- **Lead sponsor:** TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-22
- **Primary completion:** 2031-04
- **Final completion:** 2031-09
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06343402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06343402, "Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06343402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*